A model that incorporates patient-specific characteristics for those with acute myeloid leukemia may help predict mortality after treatment.
The American Society of Clinical Oncology has released a new guideline that outlines best practices for cancer clinicians when communicating with patients and their families.
Patients with breast cancer who take opioids to manage their pain are less likely to adhere to adjuvant therapy, resulting in a higher risk of death.
Approximately 170 million covered lives in oncology are potentially impacted by clinical pathways, representing 57% of the patient population. The American Society of Clinical Oncology (ASCO) has taken notice, and has actively participated in the conversation surrounding clinical pathways.
Biosimilars occupy a huge place in the oncology treatment conversation these days. But what are they exactly, and how will they impact clinical pathways?
Jennifer R Brown, MD, PhD, presented the emerging treatments and management options for front line and relapsed or refractory chronic lymphocytic leukemia today at the Clinical Pathways Congress.
A US study looking at the natural history and growth parameters of small, low-risk papillary thyroid cancers supports active surveillance as a management option.
Daratumumab-based combination therapies are ineffective in patients with multiple myeloma who have been heavily pre-treated or are refractory to one or more agents in a DCT.
Lenalidomide maintenance therapy after autologous stem-cell transplantation prolongs the time to remission in patients with multiple myeloma.
Most people diagnosed with cancer want to start treatment as soon as possible, for fear that delaying care will allow their tumor to grow out of control.